852-Overcoming T Cell Tolerance
This research article describes a novel "TCR turbocharging" pipeline designed to enhance the effectiveness of T cell receptors used in cancer immunotherapy. Scientists focused on a specific receptor, TCR156, which targets a prostate cancer antigen but naturally lacks the strength to eliminate tumors due to immune tolerance. By engineering specialized interactions called catch bonds, which strengthen under mechanical force, the researchers created variants like S32Mα that exhibit significantly higher potency. These modified T cells demonstrated a superior ability to shrink tumors in animal…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.